CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Sitagliptin +3 moredrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00820573
NCT00820573Phase 4Completed
CompareCT.gov

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With Type 2 Diabetes Mellitus

The University of Texas Health Science Center at San Antonio·interventional·Posted Jan 12, 2009·Updated Dec 13, 2013

In Brief

A Phase 4 clinical trial evaluating Sitagliptin, Metformin, and 2 other interventions for Diabetes. Completed, enrolled 16 participants across 1 site.

Detailed Summary

In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after 6 weeks of treatment: Objective: To assess the effects of co-administration of sitagliptin and metformin compared to placebo on hepatic glucose production (HGP). Hypothesis: After 6 weeks of treatment, the co-administration of sitagliptin and metformin provides greater reduction in hepatic glucose production (HGP) compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 12, 2009
Enrollment StartOct 1, 2009
Primary CompletionJun 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.5 years ago

Interventions

Sitagliptindrug

tablet, 100 mg/day, 6 weeks

Metformindrug

tablet, 1000 mg/ bid, 6 weeks

Sitagliptin + Metformindrug

tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks

Placebodrug

Placebo 6 weeks